Clinical Trial: A Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 and EU-Phesgo(R).

U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07495930) titled 'A Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 and EU-Phesgo(R).' on March 22.

Brief Summary: The study is being conducted to compare the pharmacokinetic (PK) parameters of HLX319 and EU-Phesgo(R) after a single subcutaneous administration in healthy male subjects in China, providing a basis for the design of subsequent clinical study protocols.

Study Start Date: April 30

Study Type: INTERVENTIONAL

Condition: Health Adult Subjects

Intervention: DRUG: HLX319

HLX319 is a biosimilar of pertuzumab-trastuzumab monoclonal antibody injection (subcutaneous injection).

DRUG: EU-P...